Urogen Pharma (URGN) Competitors $18.56 -0.81 (-4.18%) As of 01:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock URGN vs. APLS, MLTX, INDV, SRRK, VKTX, KYMR, XENE, AMRX, ARWR, and RAREShould you be buying Urogen Pharma stock or one of its competitors? The main competitors of Urogen Pharma include Apellis Pharmaceuticals (APLS), MoonLake Immunotherapeutics (MLTX), Indivior (INDV), Scholar Rock (SRRK), Viking Therapeutics (VKTX), Kymera Therapeutics (KYMR), Xenon Pharmaceuticals (XENE), Amneal Pharmaceuticals (AMRX), Arrowhead Pharmaceuticals (ARWR), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "pharmaceutical products" industry. Urogen Pharma vs. Its Competitors Apellis Pharmaceuticals MoonLake Immunotherapeutics Indivior Scholar Rock Viking Therapeutics Kymera Therapeutics Xenon Pharmaceuticals Amneal Pharmaceuticals Arrowhead Pharmaceuticals Ultragenyx Pharmaceutical Apellis Pharmaceuticals (NASDAQ:APLS) and Urogen Pharma (NASDAQ:URGN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings. Does the media prefer APLS or URGN? In the previous week, Apellis Pharmaceuticals had 17 more articles in the media than Urogen Pharma. MarketBeat recorded 20 mentions for Apellis Pharmaceuticals and 3 mentions for Urogen Pharma. Urogen Pharma's average media sentiment score of 1.76 beat Apellis Pharmaceuticals' score of 0.99 indicating that Urogen Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apellis Pharmaceuticals 13 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Urogen Pharma 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do institutionals & insiders hold more shares of APLS or URGN? 96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are owned by institutional investors. 6.8% of Apellis Pharmaceuticals shares are owned by insiders. Comparatively, 4.7% of Urogen Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts rate APLS or URGN? Apellis Pharmaceuticals currently has a consensus price target of $34.12, indicating a potential upside of 23.53%. Urogen Pharma has a consensus price target of $32.00, indicating a potential upside of 72.41%. Given Urogen Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Urogen Pharma is more favorable than Apellis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apellis Pharmaceuticals 0 Sell rating(s) 9 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.58Urogen Pharma 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is APLS or URGN more profitable? Apellis Pharmaceuticals has a net margin of -30.24% compared to Urogen Pharma's net margin of -164.44%. Apellis Pharmaceuticals' return on equity of -116.09% beat Urogen Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Apellis Pharmaceuticals-30.24% -116.09% -26.72% Urogen Pharma -164.44%-97,487.15%-59.38% Which has more volatility & risk, APLS or URGN? Apellis Pharmaceuticals has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500. Comparatively, Urogen Pharma has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Which has better earnings and valuation, APLS or URGN? Urogen Pharma has lower revenue, but higher earnings than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApellis Pharmaceuticals$781.37M4.46-$197.88M-$1.82-15.18Urogen Pharma$90.40M9.50-$126.87M-$3.32-5.59 SummaryApellis Pharmaceuticals beats Urogen Pharma on 9 of the 16 factors compared between the two stocks. Get Urogen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding URGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart URGN vs. The Competition Export to ExcelMetricUrogen PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$863.44M$3.09B$5.75B$9.85BDividend YieldN/A2.28%6.66%4.49%P/E Ratio-5.6220.8882.7926.52Price / Sales9.50369.93499.49162.43Price / CashN/A43.5325.7028.92Price / Book-9.198.0310.786.50Net Income-$126.87M-$53.35M$3.28B$266.34M7 Day Performance-3.53%-1.05%-0.42%-1.25%1 Month Performance-6.64%5.84%6.47%3.30%1 Year Performance32.86%10.76%49.47%23.59% Urogen Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)URGNUrogen Pharma4.593 of 5 stars$18.56-4.2%$32.00+72.4%+42.8%$863.44M$90.40M-5.62200APLSApellis Pharmaceuticals4.3009 of 5 stars$28.05+0.4%$34.12+21.6%-28.4%$3.54B$781.37M-15.40770News CoveragePositive NewsMLTXMoonLake Immunotherapeutics2.4637 of 5 stars$55.02+1.0%$74.43+35.3%+28.5%$3.54BN/A-19.812News CoveragePositive NewsAnalyst RevisionINDVIndivior2.9401 of 5 stars$24.32-0.6%$22.00-9.5%+102.7%$3.35B$1.17B39.221,051SRRKScholar Rock4.6177 of 5 stars$33.99+0.6%$45.75+34.6%+277.8%$3.27B$33.19M-11.70140News CoveragePositive NewsVKTXViking Therapeutics4.2674 of 5 stars$26.97+3.6%$86.92+222.4%-54.1%$3.03BN/A-17.6220Positive NewsAnalyst RevisionKYMRKymera Therapeutics3.4743 of 5 stars$41.93-4.4%$58.76+40.2%-6.5%$3.00B$47.07M-12.08170News CoveragePositive NewsXENEXenon Pharmaceuticals2.6945 of 5 stars$38.80+0.4%$53.20+37.1%-3.3%$2.99B$9.43M-10.92210News CoveragePositive NewsAnalyst ForecastOptions VolumeAMRXAmneal Pharmaceuticals3.0514 of 5 stars$9.36-0.3%$11.60+24.0%+12.4%$2.94B$2.79B935.448,100Positive NewsARWRArrowhead Pharmaceuticals4.2066 of 5 stars$21.18+0.0%$43.14+103.7%+21.3%$2.93B$572.98M-16.54400News CoverageAnalyst ForecastRAREUltragenyx Pharmaceutical4.5038 of 5 stars$30.34+2.6%$81.50+168.6%-43.4%$2.92B$560.23M-5.481,294News Coverage Related Companies and Tools Related Companies Apellis Pharmaceuticals Competitors MoonLake Immunotherapeutics Competitors Indivior Competitors Scholar Rock Competitors Viking Therapeutics Competitors Kymera Therapeutics Competitors Xenon Pharmaceuticals Competitors Amneal Pharmaceuticals Competitors Arrowhead Pharmaceuticals Competitors Ultragenyx Pharmaceutical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:URGN) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersThis Massive Market is Ripe for Disruption by this NasdaqFanatics Hit $31B. This Nasdaq Company Is Building the Next Wave Fanatics built a merch empire by owning th...i2i Marketing Group, LLC | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored“Shadow Group” in Washington, DC Could Crash MarketNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Urogen Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share Urogen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
